Clinical trial
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
NCT00049127 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00049127 |
|---|---|
| Title | Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor |
| Official title | Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Adult Anaplastic Oligodendroglioma, Adult Mixed Glioma, Adult Oligodendroglioma, Recurrent Adult Brain Neoplasm |
| Intervention type | Drug, Other |
| Interventions | Imatinib Mesylate, Laboratory Biomarker Analysis, Pharmacological Study |
| Enrollment | 64 |
| Start date | Jun 1, 2003 |
| Primary completion | Aug 1, 2011 |
| Completion | Sep 1, 2019 |
| First posted | Jan 27, 2003 |
| Last update posted | Oct 21, 2019 |
| Countries | United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: